reference/30152797

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30152797

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase I\|Journal Article
endingPage	6255
issn	1078-0432 1557-3265
issueIdentifier	17
pageRange	6247-6255
publicationName	Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage	6247
bibliographicCitation	Talpaz M, Rakhit A, Rittweger K, O'Brien S, Cortes J, Fettner S, Hooftman L, Kantarjian H. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res. 2005 Sep 01;11(17):6247–55. doi: 10.1158/1078-0432.ccr-05-0882. PMID: 16144928.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cbef71c6c9ee38c2d2fb7df759bcb6c6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c8c1de7da4deb440ed2ecc8697edce38 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_230da5d17af4beb2cc1ee6fe50d602f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cf55cb5b0fa4a95a78ce85505831598f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d123a6e53fa423e9c7b399623849011 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-8636-1071 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_beda2e18dc151b95eecbf6c698b7d3a5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b1319d2120618172d4992c73da396c2b http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3361-3981 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2179b74e09e09468d620914757116d27
date	2005-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/16144928 https://doi.org/10.1158/1078-0432.ccr-05-0882
isPartOf	https://portal.issn.org/resource/ISSN/1078-0432 https://portal.issn.org/resource/ISSN/1557-3265 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia
discusses	http://id.nlm.nih.gov/mesh/M0005564 http://id.nlm.nih.gov/mesh/M0018641 http://id.nlm.nih.gov/mesh/M0025711 http://id.nlm.nih.gov/mesh/M0552528 http://id.nlm.nih.gov/mesh/M0006822 http://id.nlm.nih.gov/mesh/M0006823 http://id.nlm.nih.gov/mesh/M0017182 http://id.nlm.nih.gov/mesh/M0263641
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D015464Q000188 http://id.nlm.nih.gov/mesh/D000971Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D000077190 http://id.nlm.nih.gov/mesh/D004338 http://id.nlm.nih.gov/mesh/D004337 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D011092Q000493 http://id.nlm.nih.gov/mesh/D011092Q000008 http://id.nlm.nih.gov/mesh/D000971Q000493 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D015464Q000473 http://id.nlm.nih.gov/mesh/D016898Q000008 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D016898Q000493 http://id.nlm.nih.gov/mesh/D003561Q000493 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D011994 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D011092Q000009 http://id.nlm.nih.gov/mesh/D003561Q000009 http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D003561Q000008 http://id.nlm.nih.gov/mesh/D016898Q000009
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8167 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID596 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_850d3dd3f0465864f03b25f855d284d1 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135398721 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6253 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9727

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127537750 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129367670

Total number of triples: 73.